Ticker Details
Medpace Holdings, Inc. Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
IPO Date:	August 11, 2016
Sector:	Healthcare
Industry:	Medical Diagnostics and Research
Market Cap:	$17.33B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.50 | 1.80%
Avg Daily Range (30 D):	$10.94 | 1.93%
Avg Daily Range (90 D):	$9.61 | 1.91%

Institutional Daily Volume
Avg Daily Volume:	.28M
Avg Daily Volume (30 D):	.26M
Avg Daily Volume (90 D):	.3M

Trade Size
Avg Trade Size (Sh.):	42
Avg Trade Size (Sh.) (30 D):	19
Avg Trade Size (Sh.) (90 D):	21

Institutional Trades
Total Institutional Trades:	3,322
Avg Institutional Trade:	$7.21M
Avg Institutional Trade (30 D):	$20.19M
Avg Institutional Trade (90 D):	$18.64M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$8.89M
Avg Closing Trade (30 D):	$21.78M
Avg Closing Trade (90 D):	$22.49M
Avg Closing Volume:	41.37K

News

Jun 8, 2026 @ 6:00 PM Safirstein Law LLC Announces That A Class Action L... Source: Safirstein Law Llc

Jun 7, 2026 @ 9:55 PM MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR CO... Source: Rosen Law Firm

Jun 5, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Medpace Ho... Source: Bronstein, Gewirtz & Grossman Llc

Jun 5, 2026 @ 12:46 AM ROSEN, A LEADING LAW FIRM, Encourages Veritone, In... Source: Rosen Law Firm

Jun 4, 2026 @ 11:18 PM MEDPACE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL,... Source: Rosen Law Firm

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$17.37	$4.31	$4.35
Diluted EPS	$17.03	$4.25	$4.28
Revenue	$2.78B	$707.33M	$706.6M
Gross Profit	$800.22M	$201.64M	$196.33M
Net Income / Loss	$491.5M	$121.36M	$123.87M
Operating Income / Loss	$583.4M	$146.82M	$141.5M
Cost of Revenue	$1.98B	$505.69M	$510.28M
Net Cash Flow	$456.36M	$-149.99M	$155.63M
PE Ratio